No Data
Overseas income has been declining year after year, zhejiang orient gene biotech sets up a new subsidiary to seek the Southeast Asian market.
①Zhejiang Orient Gene Biotech expands its wholesale trade business of medical instruments by establishing a new company in the Philippines, and expands its market in Southeast Asia and South Asia. ②Currently, Zhejiang Orient Gene Biotech's key overseas markets are mainly in the Americas and Europe, but in recent years, the revenue from overseas markets has been rapidly declining.
Zhejiang Orient Gene Biotech to Set Up Philippine Subsidiary for $1.2 Million
Zhejiang Orient Gene Biotech (688298.SH) plans to establish a holding company in the Philippines to engage in the wholesale trade business of medical instruments.
zhejiang orient gene biotech (688298.SH) announced that its wholly-owned subsidiary Healgen Inte...
Zhejiang Orient Gene Biotech (688298.SH): Intends to jointly invest with related parties to establish a holding company
Zhejiang Orient Gene Biotech(688298.SH) announced on September 11 that, based on the company's global strategy, and in order to expand into the Southeast Asian market, the company, through its wholly-owned subsidiary, Zhejiang Orient Gene International Holdings, jointly invested with Mr. Fang Xiaoliang and Ms. Li Rongzhen to establish a new company, Hengjian, in the Philippines, with a total investment of 1.2 million US dollars. The registered capital of the new company is 0.34 million US dollars, equivalent to 20 million pesos, with 2 million ordinary shares with voting rights, with a par value of 10 pesos per share. Among them, Zhejiang Orient Gene International Holdings has committed to contribute 19,999,980.00 pesos and holds 1,999,998 shares.
Zhejiang Orient Gene Biotech's Unit Gets Certificate to Conduct Research in US
Zhejiang Orient Gene Biotech (688298.SH): accumulated repurchased 8.3327 million shares of the company's stock.
On September 2, Gelon Hui announced that as of August 31, 2024, Zhejiang Orient Gene Biotech (688298.SH) had repurchased a total of 8.3327 million shares of the company through the Shanghai Stock Exchange system through centralized competitive bidding, accounting for 4.13% of the total share capital of 201.6 million shares. The lowest price for repurchase transactions was 27.83 yuan per share, the highest price was 34.50 yuan per share, and the total amount paid for the repurchase was 0.275 billion yuan.
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Using Debt Sensibly?No Data
No Data
